Diarrhea News and Research

Latest Diarrhea News and Research

Vertex receives positive opinion from European CHMP for approval of KALYDECO for cystic fibrosis

Vertex Pharmaceuticals Incorporated today announced that the European Committee for Medicinal Products for Human Use has issued a positive opinion recommending the approval of KALYDECO (ivacaftor) for people with cystic fibrosis (CF) ages 6 and older who have one of eight non-G551D gating mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.

28 Jun 2014

Noroviruses responsible for almost a fifth of all cases of acute gastroenteritis

Noroviruses are a leading cause of acute gastroenteritis (diarrhoea and vomiting) across all age groups, responsible for almost a fifth (18%) of all cases worldwide. New estimates, published in The Lancet Infectious Diseases, highlight the importance of developing norovirus vaccines, say the authors.

27 Jun 2014

Preventing antibiotic side effects: an interview with Florence Séjourné, CEO, Da Volterra

Like all drugs, antibiotics can have side-effects when administered to people. The most common (and often benign) side effect people experience when taking antibiotics is “associated diarrhea”. This illustrates the fact that antibiotics have an impact on the intestine!

25 Jun 2014

Gelesis100 capsule leads to greater weight loss in overweight, obese individuals

A new "smart pill" called Gelesis100 safely leads to greater weight loss in overweight and obese individuals compared with those who receive an active comparator/placebo capsule, while all subjects have similar diet and exercise instructions, an international multicenter study finds.

24 Jun 2014

Forest Laboratories reports positive results from three Phase III trials of vilazodone for GAD treatment

Forest Laboratories, Inc. today announced positive topline results from three Phase III trials evaluating the efficacy, safety and tolerability of vilazodone in adult patients with generalized anxiety disorder (GAD).

24 Jun 2014

Clovis Oncology begins TIGER2 study for treatment of NSCLC patients with EGFR/T790M mutations

Clovis Oncology, Inc. announced today that the TIGER2 study has commenced with the dosing of the first patient at a U.S. study site.

23 Jun 2014

Cubist Pharmaceuticals' SIVEXTRO receives FDA approval for treatment of ABSSSI

Cubist Pharmaceuticals, Inc. announced today the U.S. Food and Drug Administration approved SIVEXTRO (tedizolid phosphate) for the treatment of adult acute bacterial skin and skin structure infections (ABSSSI).

21 Jun 2014

Debiopharm launches Phase 1 study of anti-infective agent Debio 1450

Debiopharm Group, a Swiss-based global biopharmaceutical company developing prescription drugs that target unmet medical needs as well as companion diagnostics, today announced the launch of a Phase 1 dose-escalation study of Debio 1450 (previously known as AFN-1720), a highly potent anti-infective agent that is selectively active against a large number of Staphylococcus species, including all known resistant strains such as methicillin-resistant S. aureus (MRSA) and vancomycin-intermediate S. aureus (VISA).

19 Jun 2014

Research explores links between planet's health and human health

United Nations University will help pioneer a fresh trail in global health research, exploring links between the planet's health and human health at an institute in Kuala Lumpur generously supported by Malaysia.

17 Jun 2014

C. difficile bacteria pose major health threat without proper infection prevention in hospitals, homes

Without proper infection prevention in hospitals, and now homes, the Clostridium difficile bacteria poses a major health threat, cautions a Case Western Reserve University infection control researcher.

17 Jun 2014

Alexion announces that FDA grants ODD to Soliris for Myasthenia Gravis treatment

Alexion Pharmaceuticals (Nasdaq:ALXN) today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to Soliris® (eculizumab) for the treatment of patients with Myasthenia Gravis (MG), a rare, debilitating neurologic disorder caused by uncontrolled complement activation.

17 Jun 2014

Osteoarthritis patients treated with SoluMatrix meloxicam report greater pain relief

Iroko Pharmaceuticals, LLC, a global specialty pharmaceutical company dedicated to advancing the science of analgesia, today will present Phase 3 results that showed osteoarthritis (OA) patients treated with investigational SoluMatrix meloxicam 5 mg and 10 mg, a low dose nonsteroidal anti-inflammatory drug (NSAID), reported significantly greater pain relief compared with placebo.

12 Jun 2014

Celgene: OTEZLA phase III study for psoriatic arthritis meets primary endpoint

Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation (NASDAQ:CELG), today announced results of additional analyses from the phase III clinical trials of OTEZLA, the Company's oral, selective inhibitor of phosphodiesterase 4 (PDE4).

11 Jun 2014

Synthetic, Enterome partner to study effects of beta-lactam antibiotics on gastrointestinal microflora

Synthetic Biologics, Inc., a developer of novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases, and Enterome Bioscience SA, a pioneer in the development of innovative disease management solutions based on a deep understanding of the gut microbiome, today announced that they have entered into an agreement to conduct metagenomic research on the effects of beta-lactam antibiotics on the gastrointestinal microflora (microbiome) of human patients.

10 Jun 2014

FDA accepts Pharmacyclics' IMBRUVICA sNDA for review

Pharmacyclics, Inc. today announced that the U.S. Food and Drug Administration has accepted for filing its supplemental New Drug Application (sNDA) to support the review of IMBRUVICA (ibrutinib) in the treatment of patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) who have received at least one prior therapy for a full approval.

9 Jun 2014

BioDelivery Sciences receives approval of NDA for BUNAVAIL from FDA

BioDelivery Sciences International, Inc. received approval of the New Drug Application (NDA) for BUNAVAIL™ (buprenorphine and naloxone) buccal film (CIII) from the U.S. Food and Drug Administration (FDA).

9 Jun 2014

Cubist Pharmaceuticals publishes positive results from Phase 3 clinical trial of SIVEXTRO

Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced that The Lancet Infectious Diseases published online the positive results from ESTABLISH-2, a pivotal Phase 3 clinical trial of the investigational antibiotic SIVEXTRO™ (tedizolid phosphate), which is being developed for the treatment of acute bacterial skin and skin structure infections (ABSSSI) and complicated skin and soft tissue infections (cSSTI).

9 Jun 2014

Probiotics effectively prevent hepatic encephalopathy in patients with cirrhosis of the liver

Probiotics are effective in preventing hepatic encephalopathy in patients with cirrhosis of the liver, according to a new study in Clinical Gastroenterology and Hepatology, the official clinical practice journal of the American Gastroenterological Association. Hepatic encephalopathy is a deterioration of brain function that is a serious complication of liver disease.

9 Jun 2014

U.S. Preventive Services Task Force recommends hepatitis B screening for high risk individuals

A simple blood test can detect if a person is one of the two billion people worldwide infected with hepatitis B. And now the U.S. Preventive Services Task Force recommends that all teens and adults who are high risk for hepatitis B get screened for the infection.

6 Jun 2014

Naloxegol holds hope for opioid-induced constipation

Pain medicines often lead to constipation for patients seeking long-term pain relief, but an investigational once-daily drug may help, according to study led by the University of Michigan Health System.

5 Jun 2014

Diarrhea News and Research

Latest Diarrhea News and Research

Vertex receives positive opinion from European CHMP for approval of KALYDECO for cystic fibrosis

Noroviruses responsible for almost a fifth of all cases of acute gastroenteritis

Preventing antibiotic side effects: an interview with Florence Séjourné, CEO, Da Volterra

Gelesis100 capsule leads to greater weight loss in overweight, obese individuals

Forest Laboratories reports positive results from three Phase III trials of vilazodone for GAD treatment

Clovis Oncology begins TIGER2 study for treatment of NSCLC patients with EGFR/T790M mutations

Cubist Pharmaceuticals' SIVEXTRO receives FDA approval for treatment of ABSSSI

Debiopharm launches Phase 1 study of anti-infective agent Debio 1450

Research explores links between planet's health and human health

C. difficile bacteria pose major health threat without proper infection prevention in hospitals, homes

Alexion announces that FDA grants ODD to Soliris for Myasthenia Gravis treatment

Osteoarthritis patients treated with SoluMatrix meloxicam report greater pain relief

Celgene: OTEZLA phase III study for psoriatic arthritis meets primary endpoint

Synthetic, Enterome partner to study effects of beta-lactam antibiotics on gastrointestinal microflora

FDA accepts Pharmacyclics' IMBRUVICA sNDA for review

BioDelivery Sciences receives approval of NDA for BUNAVAIL from FDA

Cubist Pharmaceuticals publishes positive results from Phase 3 clinical trial of SIVEXTRO

Probiotics effectively prevent hepatic encephalopathy in patients with cirrhosis of the liver

U.S. Preventive Services Task Force recommends hepatitis B screening for high risk individuals

Naloxegol holds hope for opioid-induced constipation

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Bioprocess Efficiency with Cell Density Monitoring

Diarrhea News and Research

Latest Diarrhea News and Research

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Bioprocess Efficiency with Cell Density Monitoring

Newsletters you may be interested in